GlassScriptPhysician profile
Robert Steven Meadows
NPI 1386667343
$151,486.69
in general payments reported to CMS, 2019-2025
56 companies · $36K in 2025
The $36K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,810 · 2020: $13K · 2021: $17K · 2022: $10K · 2023: $34K · 2024: $32K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Consulting Fee: $16K · Food and Beverage: $12K · Travel and Lodging: $8,334 · Education: $65.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,576.64 |
| Consulting Fee | $16,250.00 |
| Food and Beverage | $12,146.90 |
| Travel and Lodging | $8,333.69 |
| Education | $65.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $61,197.27 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lilly USA, LLC | $44,096.22 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Neurocrine Biosciences, INC. | $27,755.88 | 2019-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $2,682.34 | 2019-2025 | Mavenclad, Mavenclad |
| Livanova USA, INC. | $2,590.57 | 2020-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $1,550.59 | 2021-2025 | |
| Biogen, INC. | $1,001.67 | 2019-2024 | Tysabri, Vumerity, Leqembi |
| Sunovion Pharmaceuticals INC. | $929.60 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $849.19 | 2019-2024 | |
| Pfizer INC. | $693.22 | 2019-2025 | |
| Mdd US Operations, LLC | $654.04 | 2019-2025 | Apokyn, Xadago, Apokyn |
| Amgen INC. | $619.41 | 2019-2022 | |
| Boston Scientific Corporation | $553.84 | 2022-2025 | Vercise |
| Ucb, INC. | $534.72 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Sk Life Science, INC. | $480.82 | 2020-2023 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.